Fancy that - Europe's biggest drug makers said to bid for InterMune
Oh look, I see Bloomberg and Reuters are both reporting that InterMune has attracted several suitors, including GlaxoSmithKline, Actelion, Roche and Sanofi:..
A cheeky website about deals, dealmakers and anything else I find interesting. Edited by Ben Harrington. If you have a tip, want to discuss a story or have a subscription enquiry please feel free to email Betaville at [email protected]. Betaville can also be reached at Whats App, Signal or Telegram. Betaville's Twitter handle is @bharringtonw11 and you can message me via Twitter with stories.
Oh look, I see Bloomberg and Reuters are both reporting that InterMune has attracted several suitors, including GlaxoSmithKline, Actelion, Roche and Sanofi:..
Will the uber-acquisitive Liberty Global/Virgin Media step in with a £500 million plus counter offer for telecoms and IT company Daisy Group?..
It sounds like this InterMune situation is heating up.
Good sources tell me InterMune - a US-based bio-pharmaceutical company that specialises in making a drug to treat idiopathic pulmonary fibrosis - has begun working with bankers from Evercore alongside long-standing financial adviser Goldman Sachs to look at 'strategic options' for the business.
It is believed the appointment of Evercore may lead to a formal auction of InterMune...
Construction group Carillion appears to be very keen to pursue a £3 billion merger with Balfour Beatty despite Balfour's intransigence towards a deal...
I have had a lot of enquiries from loyal Betaville readers in recent weeks about Orange since I published my German Orange article back in June. In case you don't remember, here is a link to the article: http://betaville123.blogspot.co.uk/2014/06/a-german-orange.html..
Alistair Osborne, one of my former colleagues and bosses from The Daily Telegraph, is clearly refreshed after having some time off.
Indeed, Osborne's column today in The Times is highly entertaining and worthwhile a read, especially the item about Walgreen and Boots.
If you haven't looked at it already, here is a link to Osborne's column:..
I have been hearing some pretty interesting things recently about a German drug developer called Evotec AG.
To be honest, it's not clear to me exactly what is going on with this stock.
Geoff Foster, though, recently suggested that a British pharmaceutical company was lining up a EURO 5 a share offer for the business...
Things are going from bad to worse at Bank of America Merrill Lynch's European investment banking team...
Remember that bizarre statement that Mike Ashley's Sports Direct put out a few weeks ago regarding shoe retailer Office?..
Looking over this morning's coverage of British American Tobacco's recent figures, I see a couple of newspaper reporters tried to tempt Nicandro Durante, CEO of BAT, into spilling the beans about whether the tobacco giant has any plans to consolidate its position in the US...
As chief executives, entrepreneurs and City dealmakers slope off to the Mediterranean for August
(islands off the Italian coast appear to be particularly in vogue at the moment), I am going to look at a few more "off-beat" stories. ..
Quelle surprise - another Bank of America Merrill Lynch bear hug has fallen over.
This year the Wall Street investment bank has advised several companies trying to buy rival businesses using a "bear hug", an aggressive tactic used in M&A to force the the target company to the negotiating table by making an indicative offer public.
It looks like Pepsi's long-only shareholders are really piling the pressure on the company to give Nelson Peltz seats on the consumer giant's board...
I see Apple chip maker Dialog Semiconductor and AMS have called off their SFr4 billion merger...
Now that the £32 billion AbbVie/Shire deal looks to be "done" (or at least for the time being), it's time to look at another potential deal brewing in the sector...
I see there is no mention of Lazard in this morning's $53 billion deal announcement from AbbVie and Shire (for readers unfamiliar with this ongoing tale it might be worthwhile clicking here: http://betaville123.blogspot.co.uk/2014/06/whats-missing-from-abbvies-27-billion.html)...
It struck me the other day that amid the recent IPO euphoria there appeared to be fewer foreign companies coming to list on the London market...
I see British American Tobacco has finally put on an announcement effectively confirming my story on the front page of The Times a few months ago...
I bet property consultant WSP is feeling rather relieved that it didn't press ahead with the purchase of Sweett Group at the beginning of the year.
For readers that don't recall, I had a story that WSP - which is owned by Canada-based Genivar Inc - was on the verge of buying Sweett Group in early January but pulled out of the deal around the time the Aim-listed business made this announcement:
..
[Disclaimer - the information on Betaville does not consitute any form of investment recommendation and is not intended to be relied upon by readers in making, or refraining from, any investment decisions].